Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06051253

TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease

Efficacy of Infliximab Treatment Based on TDM (Therapeutic Drug Monitoring) in Adult Patients With Active Perianal Fistulizing Crohn's Disease

Sponsor: Asan Medical Center

Conditions Crohn Disease Infliximab Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score Perianal Fistula Due to Crohn's Disease Therapeutic Drug Monitoring

Interventions Standard infliximab intravenous therapy TDM-based infliximab intravenous therapy

Updated 5 times since 2023 Last updated: May 11, 2024 Started: Nov 1, 2023 Primary completion: Jun 30, 2026 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Crohn Disease and Infliximab, this trial is actively recruiting participants. The trial is conducted by Asan Medical Center and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE4
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Oct 2023 — Jun 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asan Medical Center

Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea